MedTrace Logo

Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery

NCT00967447 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2025-02-11

Study results available
· View outcomes & findings →

Summary

Open, prospective, uncontrolled, observational cohort study.

Conditions

  • Thromboembolism
  • Arthroplasty, Replacement, Hip

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-01
Primary Completion
2010-01-01

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00967447 on ClinicalTrials.gov